Home › Atopic Dermatitis (Eczema) › Arkansas
Atopic Dermatitis (Eczema) clinical trials in Arkansas
8 studies for Atopic Dermatitis (Eczema) are looking for participants at sites in Arkansas.
Cities in Arkansas
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Fort Smith
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Sep 28, 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Hot Springs
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT07298395A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Arkansas Research Trials, North Little Rock
RecruitingPhase 3
Ages 2 to 11 · All sexes · Updated Sep 25, 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Dermatology Trial Associates, Inc, Bryant
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Aug 28, 2026 · NCT07599813A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Applied Research Center and Wellness Clinic /ID# 268547, Little Rock
RecruitingPhase 3
Ages 2 to 11 · All sexes · Updated Aug 6, 2026 · NCT06461897A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, North Little Rock
RecruitingPhase 3
6 Months – 11 Years · All sexes · Updated Jul 7, 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville
RecruitingPhase 3
Ages 18 to 63 · All sexes · Updated Jul 6, 2026 · NCT06389136A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- Arkansas Research Trials, North Little Rock
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 19, 2025 · NCT06055361From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.